DPT-IPV-Hib vaccine - Mitsubishi Tanabe Pharma Corporation

Drug Profile

DPT-IPV-Hib vaccine - Mitsubishi Tanabe Pharma Corporation

Alternative Names: BK 1310; MT 2355

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer BIKEN; Mitsubishi Tanabe Pharma Corporation
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 01 Jun 2017 Phase-III clinical trials in Diphtheria (In children, In infants, Prevention) in Japan (IM) (NCT03188692)
  • 01 Jun 2017 Phase-III clinical trials in Haemophilus infections (In children, In infants, Prevention) in Japan (IM) (NCT03188692)
  • 01 Jun 2017 Phase-III clinical trials in Pertussis (In children, In infants, Prevention) in Japan (IM) (NCT03188692)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top